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events were considered, reflecting the year 2015. All outcomes were discounted 
at 3.5% annually. Results: Regarding the AS subpopulation, the total treatment 
cost for IFX, ADA, CZP, ETA, GOL and CC was: € 67,736, € 38,914, € 38,721, € 38,290, 
€ 35,338 and € 4,110; and the quality-adjusted life years (QALYs) were: 10.031, 9.882, 
9.949, 9.933, 9.903 and 9.360, respectively. CZP dominated ADA and it was cost-
effective compared to ETA generating an incremental cost-effectiveness ratio 
(ICER) of € 26,848/QALY gained (willingness-to-pay threshold: € 34,000). CZP was 
less effective (-0.082 QALYs) but less costly (-€ 29,015) than IFX, whereas it was 
more effective (+0.046 QALYs) and more costly (+€ 3,383) than GOL. CZP and GOL 
provided the lowest ICERs versus CC amongst comparators. Regarding nr-axSpA, 
the total treatment cost with CC, ADA and CZP was: € 4,754, € 33,748 and € 34,625; 
and QALYs were: 10.412, 10.681 and 10.948. The ICER of CZP versus CC and ADA 
was € 55,726 and € 3,289, respectively; CZP dominated ADA. ConClusions: CZP 
may be considered a cost-effective option with respect to the alternative axSpA 
therapies in Greece.
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objeCtives: The aim of this study is to analyze healthcare costs of osteoporosis 
and to build a economic model cost-effectiveness of pharmacological intervents 
based on real world data Methods: The cost analysis was conducted taking each 
healthcare service into account during the study period (2005-2008). A hypotheti-
cal scenario based on the real-life available evidence was constructed. The mean 
level of adherence to populate the hypothetical scenario of full adherence was set 
at MPR > 80%. The model was built by adding a step value to the real-world adher-
ence of each subject so that the subject shifted to the hypotetical scenario of full 
adherence. Cost-effectiveness of full adherence compared to real-world adherence 
was expressed in terms of ICER and the number of fractures avoided was set as an 
effectiveness unit of measure. Results: The mean annual healthcare cost was 
€ 247.44 per not fractured patient and € 1,044.85 per fractured patient. The eco-
nomic model showed that the average cost of medical treatments in case of optimal 
adherence per patient/year would increase from € 88.73 in real-world adherence 
to € 125.52 in full adherence. The rising costs are compensated by a reduction in 
number of fractures, decreasing by 65%. In this scenario, also the total yearly costs 
related hospitalizations would decrease from € 319,379 in real-word adherence to 
€ 110,917 in full adherence. The ICER, expressed in terms of cost/fracture avoided 
equals € 821 (cost that the NHS should invest to avoide a fracture) ConClusions: 
This study demonstrated the potential of the use of existing data sources to evalu-
ate appropriateness of drug use. Drugs cost money to buy, but if we use them in 
an appropriate way we can also save costs in other areas. In particular enhancing 
adherence to medication may lead to reductions in the number of patients requir-
ing hospitalization.
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objeCtives: We assessed the cost-effectiveness of placing apremilast, a new oral 
treatment, before anti-TNFα in the treatment pathway in psoriatic arthritis (PsA) 
patients who had failed ≥ 2 conventional DMARDs, from a Scottish payer perspec-
tive. Methods: A lifetime Markov cohort model was developed comparing 2 treat-
ment sequences: apremilast followed by adalimumab followed by etanercept vs. 
adalimumab followed by etanercept. Non-responders moved to the next line of 
therapy, or best supportive care (BSC) as last treatment line. Response was assessed 
using the Psoriatic Arthritis Response Criteria (PsARC) at the end of trial periods, 
ranging from 12-16 weeks. A 16.5% annual dropout rate was assumed for each 
drug. Efficacy inputs were obtained from a network meta-analysis and trial results. 
Utilities were estimated from the Health Assessment Questionnaire (HAQ) and 
Psoriasis Area and Severity Index response using a published regression equation. 
The HAQ score was assumed to progress in BSC. Unit costs were sourced from the 
British National Formulary, NHS reference costs, and other published sources, with 
apremilast priced at £550/4-week cycle. A 3.5% annual discount rate was applied to 
costs and quality-adjusted life-years (QALYs). Results: The apremilast arm pro-
vided an additional 2.49 years with a PsARC response and an additional 0.78 QALYs. 
Total time spent on anti-TNFα agents was reduced by 0.33 years, and time spent 
in BSC was reduced by 2.79 years. Under base-case assumptions, placing apremi-
last before anti-TNFα was more effective and less costly (incremental QALYs: 0.71; 
cost: £11,695), resulting in a cost of £16,507/QALY gained. Structural and param-
eter assumptions were tested in sensitivity analyses, which indicated results were 
sensitive to several parameters (e.g., HAQ increase on BSC, discount rates, cost of 
BSC). ConClusions: Placing apremilast before anti-TNFα agents is cost-effective 
in PsA treatment. Apremilast has been recommended for use in Scotland for the 
management of PsA patients.
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objeCtives: Assess the model structure, treatment sequence and outcome in con-
temporary cost effectiveness analysis (CEA) studies in the US and UK. Methods: 
Studies on conventional and biologic Disease-modifying anti-rheumatic drugs 
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objeCtives: Rheumatoid arthritis (RA) is a chronic, inflammatory disorder lead-
ing to disability and reduced quality of life. Effective treatment with biologic 
disease-modifying antirheumatic drugs (bDMARDs) is a significant economic 
burden on the Italian healthcare system. Economic models comparing bDMARDs 
are commonly based on indirect treatment comparisons. The Abatacept ver-
sus Adalimumab Comparison in Biologic-Naive RA Subjects with Background 
Methotrexate (AMPLE) trial was a head-to-head randomized study comparing 
subcutaneous abatacept to adalimumab, both combined with methotrexate, in 
RA patients. This study evaluated the cost-effectiveness of abatacept relative to 
adalimumab for RA patients based on AMPLE from the Italian National Health 
Service (NHS) perspective. Methods: A decision tree was designed to compare 
the costs and health benefits of abatacept and adalimumab in a cohort of 1,000 
patients over a 2-year time horizon. Efficacy, safety and concomitant drug use 
was based on AMPLE. Health benefits were based on stringent efficacy criteria: 
American College of Rheumatology (ACR)70/90 response and the health assess-
ment questionnaire disability index (HAQ-DI). Unit costs were estimated from pub-
lished public prices for 2014. Univariate sensitivity analyses assessed uncertainty 
of model inputs. Results: Abatacept dominated adalimumab in the treatment of 
RA patients with its higher effectiveness and lower costs over 2 years. Total health 
benefits were higher for abatacept compared to adalimumab, with 18, 63 and 
53 additional patients achieving ACR70, ACR90 and HAQ-DI response. Total costs 
favoured abatacept over adalimumab, with cost-savings of € 237,246. Cost-savings 
were due to lower costs for bDMARDs (-€ 262,527), treatment-related serious AEs 
(-€ 121,764), and local injection site reactions (-€ 14,047). Sensitivity analyses show 
that the cost-savings are robust while the difference in health benefits is sensi-
tive to parameter variation. ConClusions: For the Italian NHS, abatacept is less 
costly and more effective than adalimumab for RA patients according to ACR70, 
ACR 90, and HAQ-DI outcomes based on the AMPLE trial.
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objeCtives: Psoriatic arthritis (PsA) treatment may involve use of biologic injec-
tions/infusions. Apremilast was recently approved for treatment of adults with 
active PsA. Oral apremilast is priced significantly lower than biologics. Published 
comparative healthcare cost data are lacking for PsA patients receiving apremilast 
vs. biologics in a real-world care setting. We compared healthcare costs among 
PsA patients initiating apremilast or a biologic from the US managed care perspec-
tive. Methods: Adults with ≥ 2 diagnosis codes for PsA (ICD-9:696.0) were selected 
from the 2014-2105 MarketScan Commercial and Medicare Supplemental database. 
The first prescription date was defined as the index date; patients had to be continu-
ously enrolled for ≥ 6 months pre-index and ≥ 3 months post-index. To ensure new 
patient starts, biologic users had to be treatment-naïve to index medication in the 
pre-index period, although prior use of another biologic was not reason for exclu-
sion. Healthcare costs (2014 US$) were defined as the sum of pharmacy+medical 
service costs (e.g., inpatient, outpatient [including intravenous infusions], emer-
gency, and all other services [laboratory, radiology, other ancillary services]). Results, 
expressed as cost/patient/month, were reported separately for disease-specific PsA 
costs. Results: 469 (apremilast) and 1,120 (biologics) patients met inclusion cri-
teria; mean enrollment post-index was 5.6 and 6.5 months, respectively. Baseline 
demographics were balanced between cohorts, except mean age (apremilast: 52.9y; 
biologics: 49.8y; P< 0.001) and mean Charlson Comorbidity Index score (apremilast: 
0.8; biologics: 0.7; P= 0.016). Mean monthly costs for initiating apremilast vs. biologics 
were: all healthcare, $3,198 vs. $4,247 (P< 0.001); all PsA-related healthcare, $2,301 vs. 
$3,447 (P< 0.001), including PsA-related pharmacy, $2,095 vs. $2,617 (P< 0.001); PsA-
related inpatient, $43 vs. $48 (P= 0.776); PsA-related emergency, $4 vs. $10 (P= 0.456); 
PsA-related outpatient, $155 vs. $767 (P< 0.001); and all other PsA-related services, 
$4 vs. $5 (P= 0.748). ConClusions: Apremilast cost less than biologics, with aver-
age savings of ≈$1,000/patient/month based on lower PsA-related pharmacy and 
PsA-related outpatient costs.
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objeCtives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) in 
the treatment of axial spondyloarthritis (axSpA), including ankylosing spondy-
litis (AS) and non-radiographic axSpA (nr-axSpA), from a Greek payer perspec-
tive. Methods: A Markov model was locally adapted to evaluate the health effects 
and associated costs of CZP, adalimumab (ADA), infliximab (IFX), etanercept (ETA), 
golimumab (GOL) and conventional care (CC) in AS; and CZP, ADA and CC in nr-
axSpA. The model incorporated clinical practice patterns and the natural history 
of axSpA, following patients from treatment initiation to death. Efficacy data from 
randomized trials of comparators were included in a meta-analysis of a mixed 
treatment comparison analysis. The assessment period for AS and nr-axSpA was 
24 and 12 weeks, respectively. Direct costs for treating axSpA (medication acqui-
sition, administration, monitoring, and healthcare visits) and managing adverse 
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objeCtives: To perform comparative pharmacoeconomic analysis of application 
of tocilizumab and adalimumab in adult patient with active rheumatoid arthritis 
and intolerance and/or futility of further therapy with basic anti-inflammatory 
drugs. Methods: A pharmacoeconomic model was created basing on the data of 
ADACTA clinical trial, which included monotherapy with tocilizumab and adali-
mumab in a target population of patients (two groups, 100 patients each). Direct 
financial costs of drug therapy and cost efficiency of competing medical technolo-
gies were determined. Measures of efficiency were the reduction of DAS28 disease 
activity index compared to the initiate level; share of patients with remission of 
low disease activity according to DAS28 index; share of patients that responded to 
the therapy according to ACR20/ACR50/АCR70 criteria on week 24. Results: Costs 
of drug therapy per patient were 582,611.52 RUB for tocilizumab, and 493,680.00 
RUB for adalimumab. Cost-effectiveness in the reduction of disease activity 
according to DAS28 index were 176,548.94 in tocilizumab group, and 274,266.67 in 
adalimumab group. CER with regard to the share of patients with remission were 
1,460,179.24 and 4,701,714.29 for tocilizumab and adalimumab, respectively. Cost-
effectiveness of the achievement of low activity of rheumatoid arthritis according 
to DAS28 index also was more favorable in case of tocilizumab (1 131,284.50 and 
2,493,333.33). Therefore, cost-effectiveness was always more favorable in the group 
of tocilizumab. ConClusions: Administration of tocilizumab in adult patients with 
active rheumatoid arthritis and intolerance and/or futility of further therapy with 
basic anti-inflammatory drugs was 3 times more cost-effectiveness compared to 
adalimumab (the ratio may change depending on the efficiency value).
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objeCtives: This analysis was designed to estimate the budget impact following 
the introduction of apremilast in the treatment of active psoriatic arthritis (PsA) for 
adult patients who have failed to respond to or are intolerant to disease-modifying 
antirheumatic drugs (DMARDs) in Italy. Methods: A budget impact model was 
adapted to the Italian context using local epidemiological and cost data. The model 
was used to assess the financial impact of the introduction of apremilast to the 
market for the Italian National Health Service (NHS). The analysis was conducted 
over a 3-year time horizon considering year 2016 as baseline. We used real data of 
market consumption (IMS 2014 data), reflecting the budget holder’s perspective, and 
a 2015 real-world study concerning the healthcare resource consumption related 
to each treatment considered (apremilast, etanercept, infliximab, adalimumab, 
or ustekinumab). Market penetration of apremilast was based on manufacturer’s 
assumptions. Unit costs were taken from Italian standard sources. Frequency of 
screening and monitoring tests for each treatment was obtained from real-world 
data. Results: A total of ≈16,000 patients were considered as the model population 
at the first year, with an assumed 4%-6% annual growth rate. The introduction of 
apremilast over the next 3 years, assuming a market share of 1%-5%, 10%-15%, and 
15%-20% for the first, second, and third year, respectively, would lead to cost savings 
varying from a minimum of € 14,500,000 to a maximum of € 22,160,000 for the 3 years. 
In particular, drug savings account for 88% each year, whereas monitoring savings 
account for 7% and administration savings account for 5%. ConClusions: This 
analysis suggests that the use of apremilast for the treatment of active PsA may 
represent a cost-saving option for the Italian NHS over the first 3 years of utilisation.
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objeCtives: The study aimed to assess the cost-effectiveness of abatacept, adali-
mumab, etanercept, infliximab and golimumab in combination with methotrexate 
(MTX) in patients with Rheumatoid Arthritis (RA) who fail treatment with MTX 
from the Spanish Health System point of view. Methods: A Markov model was 
developed in MS Excel software based on a meta-analysis and an economic evalu-
ation performed by the Canadian Agency for Drugs and Technologies in Health. 
The model included 7 health states: therapy initiation; clinical response accord-
ing to ACR 50 (American College of Rheumatology (ACR) response criteria); clinical 
response according to ACR 20; no response; severe adverse events; change therapy; 
and death. The cost (€ in 2013) and effectiveness (life years (LY) in ACR 50) for each 
treatment option were collected over a 5-year time horizon using a cohort of 1,000 
Spanish patients with a mean age of 52 years. The structure and the clinical assump-
tions of the analysis were validated in a Delphi panel composed of 3 clinical experts 
in order to adapt the model to the Spanish setting. Pharmacological costs were 
estimated using the ex-factory price discounting the corresponding deduction 
according to Royal Decrees. Univariate and probabilistic sensitivity analyses were 
performed. Results: The Incremental Cost-Effectiveness Ratio of adalimumab, 
etanercept, golimumab, infliximab and abatacept came to 13,374€ , 20,943€ , 27,740€ , 
32,997€ and 41,704€ , respectively. The results of both sensitivity analyses showed the 
robustness of the model. ConClusions: The present analysis found adalimumab 
in combination with MTX to be the most cost-effective biological drug for patients 
with RA who failed treatment with MTX alone in terms of LY in ACR 50 response. 
(DMARDs) in treating RA patients published from 2008-2013 were reviewed. Various 
treatment sequences were deemed eligible for patients who had failed DMARDs. 
CEA was reviewed from a societal and payers perspective for various patient sub-
groups and treatment sequences. Results: Nine studies (5 UK and 4 US) were 
included from a larger set of 30 CEAs. All UK cost effectiveness studies were based 
on meta-analysis of RCTs and involved full incremental analysis between compara-
tors. Markov modeling framework or discrete event simulation methods were used 
with ACR or HAQ as the common effectiveness measure vs. the EULAR criteria. 
Methotrexate (MTX) was cheapest in moderate or severe RA patients who failed 
DMARDS. Cost /Quality adjusted life years(QALY) estimated for Etanercept ranged 
between £24,513 (after failing 2 DMARDS) and £28,380 (failing 2 DMARDS in moder-
ate to severe RA). Cost/QALY of £28,305 for Golimumab (failing 2 DMARDS and 1 
TNFi); £18,527 for Rituximab (failing TNFi) and £10,698 for Tocilizumab (Rituximab 
intolerant, failed DMARDS) were reported. CEA for Abatacept was $43,041 for women 
with moderate to severe RA who had either failed MTX or $45,979 with failed TNF-α 
inhibitor. Anakinra followed by non-biological therapy was found cheapest in US 
(albeit the least effective). ConClusions: Quality of reporting was good. Variation 
in treatment sequence limited direct comparison of estimates between studies. 
Seven of nine studies used micro-simulation methods and reported various treat-
ment sequences of DMARDs to be cost effective for subgroup of moderate to severe, 
bio naïve, DMARD or TNFi failure and women with RA. The hurdle for cost effec-
tiveness is raised when CEA estimates fall below payer thresholds or those of the 
cheapest alternatives.
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objeCtives: A cost-utility model was developed to assess the impact of plac-
ing apremilast, a new oral treatment, before biologics for patients with active 
psoriatic arthritis (PsA) who failed to respond to or are intolerant of conventional 
disease-modifying antirheumatic drugs (DMARDs) from a Spain payer perspec-
tive. Methods: A 20-year Markov model was developed. Treatment strategies 
consisted of apremilast before a biologic drug sequence compared with a biologic-
only sequence. Sequential biologics were adalimumab, infliximab, etanercept, and 
golimumab for both strategies. Patients who failed golimumab were assumed 
to receive best supportive care. The Psoriatic Arthritis Response Criteria was 
used as the efficacy measure. Drug response rates were obtained from a meta-
analysis. All-cause overall mortality was adjusted with a hazard ratio associated 
with PsA. Resource consumption was estimated by an expert panel, and biologic 
doses were taken from the summaries of product characteristics. The National 
Health System (NHS) perspective was considered, including the following costs: 
drug acquisition (ex-factory price with mandatory deduction), administration 
(parenteral drugs), and monitoring costs. Unit costs (€ , 2014) were obtained from 
national databases. An annual 3% discount rate was applied for costs and out-
comes. Published evidence was used to link HAQ-DI and PASI changes to utilities to 
generate quality-adjusted life-years (QALYs). Sensitivity analyses were performed 
to test model robustness. Results: The administration of apremilast before a 
sequence of biologic drugs showed higher effectiveness (9.19 QALYs) than the 
biologic-only sequence (9.12 QALYs). The strategy with apremilast implied lower 
total costs (€ 206,539) than the biologic-only sequence (€ 215,330). Under base-case 
assumptions, placing apremilast before biologic drugs is a dominant strategy and 
it remained a dominant option when the drug order in the biologic-only sequence 
was modified using sensitivity analyses. ConClusions: The administration of 
apremilast before biologic drugs is a cost-saving strategy for the NHS in the treat-
ment of patients with active PsA.
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objeCtives: Axial spondyloarthritis (axSpA) is a rheumatic disease that includes 
ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). Certolizumab 
pegol (CZP) is a PEGylated Fc-free anti-TNF indicated for the treatment of axSpA 
in Turkey. The objective of this study was to assess the cost-effectiveness of CZP 
in axSpA patients in Turkey compared to other anti-TNFs and standard care. The 
study was undertaken from a Turkish healthcare payer perspective. Methods: 
A Markov model was developed to estimate costs and outcomes associated with 
CZP and comparator treatment. The clinical response was ASAS20. A mixed treat-
ment comparison was undertaken to compare CZP with adalimumab, infliximab, 
etanercept and golimumab for the treatment of AS. Similar comparisons were 
made for the treatment of nr-axSpA, where CZP was compared with adalimumab. 
Resource utilization data were obtained via expert clinical opinion and included 
physician visits, monitoring costs, and others. Unit costs were taken from the 
Social Security Institution’s 2015 official price list. Costs and effects were evalu-
ated over a lifetime and discounted at 3% with results presented as incremental 
cost/life years gained. One-way and probabilistic sensitivity analyses were also 
conducted. Results: The base case analysis for AS, showed that CZP was equally 
effective and less costly compared to adalimumab, infliximab, etanercept and goli-
mumab. In nr-axSpA, CZP dominated adalimumab. Sensitivity analyses confirmed 
the robustness of the model. ConClusions: The present analyses showed that 
CZP is a cost-effective alternative therapy for the treatment axSpA patients in 
Turkey.
